viDA Therapeutics Inc.
logo BDC

viDA Therapeutics Inc.

viDA Therapeutics is advancing first-in-class drugs based on inhibitors of the extracellular serine protease, Granzyme B, to treat autoimmune and chronic inflammatory diseases. The company is focused on advancing their lead candidate into the clinic.

Investment year:  2012
Industry sector:  Biotechnology
Region:  Prairies and West
Website
BDC Venture Capital Partner

Dominique Bélanger

Managing Partner

v17.9.0.10395